Failure For AZ’s Imfinzi In CALLA Strengthens Keytruda’s Cervical Cancer Hold
Early Setting Left Underserved
An unexpected miss for AstraZeneca’s checkpoint inhibitor Imfinzi in cervical cancer, in the wake of other rivals dropping out, leaves Merck & Co’s Keytruda more firmly in command of the market.
